The CMT Research Foundation (CMTRF), a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth, today announced it has partnered with DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide (short DNA or RNA molecules) drugs by overcoming the delivery challenge that has limited the utility of this promising new potential gene therapy for CMT1A.

Read Full Article